C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

vu_jade May. 13 at 9:48 AM

$CCCC looks like a big pop coming here soon … Can hardly wait

0 · Reply

vu_jade May. 12 at 6:52 PM

$CCCC Buy the earnings release dip .. Going higher

0 · Reply

BioPM1989 May. 12 at 5:36 PM

$CCCC Babe... @Andysss

1 · Reply

vu_jade May. 12 at 4:09 PM

$CCCC Calm today .. constructive for new longs

0 · Reply

zawojak May. 12 at 11:28 AM

$CCCC Very good ER news as expected, lets see how market will react to this well performing early stage BIO corp.

0 · Reply

lelongduzboob May. 12 at 11:12 AM

$CCCC C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate

0 · Reply

zawojak May. 12 at 8:02 AM

$CCCC Earnings 12May

0 · Reply

Doom_Gloom_AR May. 11 at 8:54 PM

$CCCC the degraders work, just wait for trial results.

0 · Reply

zawojak May. 11 at 8:22 PM

$CCCC

0 · Reply

vu_jade May. 11 at 7:04 PM

$CCCC Chart is becoming more bullish .. Expecting 20-30% pop coming ..

0 · Reply

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

May 12, 2026, 7:00 AM EDT - 1 day ago

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Apr 9, 2026, 9:34 AM EDT - 4 weeks ago

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

2026-04-09T11:07:07.000Z - 4 weeks ago

C4 Therapeutics expands long-term partnership with Roche

Apr 9, 2026, 6:59 AM EDT - 4 weeks ago

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

2026-03-25T11:25:28.000Z - 7 weeks ago

C4 Therapeutics doses first patient in cemsidomide trial

$C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma$

Mar 25, 2026, 7:00 AM EDT - 7 weeks ago

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Mar 10, 2026, 8:00 AM EDT - 2 months ago

C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 4:01 PM EDT - 2 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 11:50 AM EST - 2 months ago

C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T10:25:32.000Z - 2 months ago

C4 Therapeutics price target raised to $7 from $5 at Barclays

2026-02-26T12:08:51.000Z - 2 months ago

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

Feb 26, 2026, 7:00 AM EST - 2 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

2026-02-23T17:07:13.000Z - 2 months ago

C4 Therapeutics price target raised to $30 from $20 at Brookline

Feb 23, 2026, 7:10 AM EST - 2 months ago

C4 Therapeutics to Participate in Upcoming March Conferences

2026-02-23T12:06:05.000Z - 2 months ago

C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial

$C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma$

Feb 23, 2026, 7:00 AM EST - 2 months ago

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Feb 11, 2026, 11:30 AM EST - 3 months ago

C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-14T12:05:59.000Z - 4 months ago

C4 Therapeutics outlines milestones through 2028

Jan 14, 2026, 7:00 AM EST - 4 months ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

2025-12-17T10:55:09.000Z - 5 months ago

C4 Therapeutics price target lowered to $5 from $10 at Barclays

Dec 3, 2025, 3:25 PM EST - 5 months ago

C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-12-02T10:40:12.000Z - 5 months ago

C4 Therapeutics initiated with a Buy at TD Cowen

Nov 25, 2025, 7:00 AM EST - 6 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

2025-11-21T21:10:22.000Z - 6 months ago

C4 Therapeutics files $400M mixed securities shelf

Nov 12, 2025, 8:30 AM EST - 6 months ago

C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-06T12:24:51.000Z - 6 months ago

C4 Therapeutics reports Q3 EPS (44c), consensus (38c)

2025-11-06T12:24:45.000Z - 6 months ago

C4 Therapeutics sees cash runway to the end of 2028

Nov 6, 2025, 7:00 AM EST - 6 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

2025-10-16T11:20:33.000Z - 7 months ago

C4 Therapeutics prices $125M underwritten offering

Oct 16, 2025, 7:08 AM EDT - 7 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

2025-10-01T11:10:58.000Z - 8 months ago

C4 Therapeutics announces trial collab, supply agreement with Pfizer

PFE

$C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma$

Oct 1, 2025, 7:00 AM EDT - 8 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

2025-09-23T10:15:16.000Z - 8 months ago

C4 Therapeutics price target raised to $10 from $5 at Wells Fargo

2025-09-22T11:15:14.000Z - 8 months ago

C4 Therapeutics price target raised to $10 from $8 at Barclays

2025-09-21T14:55:14.000Z - 8 months ago

C4 Therapeutics presents data from Phase 1 trial of cemsidomide

Sep 20, 2025, 3:00 PM EDT - 8 months ago

C4 Therapeutics Transcript: Status Update

Sep 20, 2025, 11:00 AM EDT - 8 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

2025-09-16T20:50:38.000Z - 8 months ago

C4 Therapeutics initiated with an Overweight at Barclays

2025-09-16T20:21:58.000Z - 8 months ago

C4 Therapeutics initiated with an Overweight at Barclays

Sep 4, 2025, 7:00 AM EDT - 8 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 3, 2025, 7:00 AM EDT - 9 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Aug 7, 2025, 7:00 AM EDT - 9 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Mar 3, 2025, 9:10 AM EST - 1 year ago

C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Transcript: Status Update

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Nov 20, 2024, 3:00 AM EST - 1 year ago

C4 Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 18, 2024, 8:35 AM EDT - 1 year ago

C4 Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Transcript: Study Update

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 5, 2024, 8:45 AM EDT - 1 year ago

C4 Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 15, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

Jul 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 16, 2024, 10:30 AM EDT - 2 years ago

C4 Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 12, 2023, 4:30 PM EST - 2 years ago

C4 Therapeutics Transcript: Study Update

$C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma$

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession

Aug 8, 2023, 7:00 AM EDT - 3 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

vu_jade May. 13 at 9:48 AM

$CCCC looks like a big pop coming here soon … Can hardly wait

0 · Reply

vu_jade May. 12 at 6:52 PM

$CCCC Buy the earnings release dip .. Going higher

0 · Reply

BioPM1989 May. 12 at 5:36 PM

$CCCC Babe... @Andysss

1 · Reply

vu_jade May. 12 at 4:09 PM

$CCCC Calm today .. constructive for new longs

0 · Reply

zawojak May. 12 at 11:28 AM

$CCCC Very good ER news as expected, lets see how market will react to this well performing early stage BIO corp.

0 · Reply

lelongduzboob May. 12 at 11:12 AM

$CCCC C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate

0 · Reply

zawojak May. 12 at 8:02 AM

$CCCC Earnings 12May

0 · Reply

Doom_Gloom_AR May. 11 at 8:54 PM

$CCCC the degraders work, just wait for trial results.

0 · Reply

zawojak May. 11 at 8:22 PM

$CCCC

0 · Reply

vu_jade May. 11 at 7:04 PM

$CCCC Chart is becoming more bullish .. Expecting 20-30% pop coming ..

0 · Reply

vu_jade May. 11 at 5:46 PM

$CCCC any other retards buy last week

0 · Reply

LabPsycho May. 11 at 5:08 PM

$CCCC @2tacos_plis Great explanation. How about this as a possible earning surprise - wild speculation of course, but if they have been selling the warrants, I think it is possible they could actually have more cash than the previous quarter...or at least the burn amount offset by any cash gained by warrant selling - if there was any.

2 · Reply

BioPM1989 May. 11 at 3:01 PM

$CCCC Unbelievable... Vibe trading bulls getting lucky here

1 · Reply

vu_jade May. 11 at 2:58 PM

$CCCC heating up

0 · Reply

vu_jade May. 11 at 1:50 PM

$CCCC you can’t stop us .. You can only hope to “C” Contain us Higher prices coming

0 · Reply

zawojak May. 11 at 9:35 AM

$CCCC An earnings pop would be nice here. $4

0 · Reply

vu_jade May. 8 at 6:11 PM

$CCCC 5 C’s “Cool aid”

0 · Reply

2tacos_plis May. 8 at 5:53 PM

$CCCC Well! This is shaping up to be a lot like December. The stock priced clawed upwards as though it were destined for the next leg up and of course got stage fright. You can see how much more the distribution is to accumulation. The stock price should be considerably lower and we all know how much shady companies like making shady corrections. Plus the red inverted hammer with confirmation isn’t at all discreet. 🙄🥃

2 · Reply

vu_jade May. 8 at 5:01 PM

$CCCC looks ready to fly .. $5 $7 $10

1 · Reply

Lotzofducats May. 8 at 4:16 PM

$CCCC With the run up &amp; now price drop- The earnings release that was supposed to happen Wednesday/Thusday prior to market open, is now off the table. Any speculation will have to happen next week. Maybe they feel they will have a better audience . 🧐

0 · Reply

Lotzofducats May. 8 at 3:25 PM

$CCCC With the price run up and now the drop-Any speculation of an earnings announcement ment this week just walked out the door and headed for early weekend break. Maybe next week with the earnings (surprise).

0 · Reply

vu_jade May. 8 at 2:30 PM

$CCCC Keep building

0 · Reply

Market Cap	349.27M
Revenue (ttm)	35.95M
Net Income (ttm)	-104.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-292.04%
Debt to Equity Ratio	0.00

Volume	2,314,800
Avg Vol	2,778,202
Day's Range	N/A - N/A
Shares Out	110.18M
Stochastic %K	95%
Beta	2.77
Analysts	Strong Sell
Price Target	$11.57